New research reveals that people who discontinue blockbuster slimming jabs like Wegovy and Mounjaro may regain lost weight far faster than those who stop traditional diet and exercise programs.
Research printed in a prominent health publication points out that while overweight people frequently drop a large proportion of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such medications need to be informed of the potential of fast rebound weight gain when the treatment concludes," stated researcher Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment weight in about a year and a half.
Weighing Therapies
The study, which reviewed 37 of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through lifestyle changes alone typically have a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Experts believe the mechanism of the drugs explains the amplified weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone concentrations far above than normal may cause the body to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making overeating far more likely."
A Lifelong Issue?
Medical guidelines advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts say that, given the likelihood of weight regain, the therapy might need to be life-long.
This view is reinforced by drug manufacturers, who say that the results "emphasize the long-term character of excess weight," akin to managing diseases like hypertension.
User Testimonies
Individuals who have discontinued the jabs explain a intense resurgence of cravings.
"It was like something that goes on and I was suddenly starving," recalled one woman.
The struggle is worsened if users have not established sustainable dietary or behavioural changes during therapy.
Widespread Use
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among women than males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and maintained weight loss relies on integrated lifestyle changes.
